Clinical Trial Update: The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LY500307 (selective estrogen receptor beta agonist) for negative symptoms and cognitive impairment in schizophrenia; the study was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• LY500307 (LY500307)

Snippet

Sponsor: Indiana University | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED | Results posted: 2019-07-02